(Q40927887)

24 September 2017

1 reference

title

The effects of metformin on cardiovascular risk factors (English)

1 reference

24 September 2017

1 reference

Grant PJ

1

1 reference

24 September 2017

language of work or name

1 reference

1 September 1995

1 reference

Diabetes/metabolism reviews

24 September 2017

published in

1 reference

24 September 2017

volume

11 Suppl 1

1 reference

24 September 2017

page(s)

S43-50

1 reference

Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL, and HDL levels. A population-based study

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

https://api.crossref.org/works/10.1002%2FDMR.5610110507

1 reference

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Effect of biguanides and atromid on fibrinolysis

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Treatment with low dose metformin in patients with peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Metformin and metoprolol CR treatment in non-obese men.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Plasminogen activator inhibitors--a review

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Contrasting Fibrinolytic Responses in Type 1 (Insulin-dependent) and Type 2 (Non-insulin-dependent) Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110507

7 January 2021

Identifiers

DOI

10.1002/DMR.5610110507

1 reference

24 September 2017

1 reference